Monday, 4 August 2014

BIO-TIC: Register now for ‘Bio Business’ Workshops

Registration for five 'bio-Business case' workshops organised by SusChem’s FP7 BIO-TIC project is now open. By participating in these workshops you can help shape the strategic agenda to boost the uptake of industrial biotechnology (IB) in Europe. In addition BIO-TIC has just released a series of videos that describe the project’s rationale and objectives and the IB business roadmaps that it is developing.

The BIO-TIC project is organising five 'bio-Business case' workshops during the Autumn of 2014. These events will look into five major product segments and applications of Industrial Biotechnology (IB) in Europe that promise significant potential for Europe’s industry and society by 2030.

The workshops are organised around the following topics:


Registration for all of the workshops is now open and can be accessed here via a dedicated website.

Knowledge exchange
With these workshops, the BIO-TIC project consortium aims to bring together industrial biotechnology end users (downstream) with technology providers (upstream), innovation agencies and decision makers to stimulate interconnected discussion and knowledge exchange platforms and processes.

The objective of the workshops is to:

  • Identify technological, non-technological and market hurdles for the uptake of industrial biotechnology in these sectors
  • Develop recommendations and solutions to overcome the identified hurdles
  • Contribute to the development, testing and fine-tuning of the BIO-TIC roadmaps
  • Bring together industrial biotechnology end users (downstream) with technology providers (upstream), innovation agencies and decision makers to stimulate interconnected discussion and knowledge exchange platforms and processes
  • Collect data to develop draft indicators to measure the socio-economic and environmental impact of IB and the use of renewables-based products in the European Union

BIO-TIC videos
Funded by the European Commission, BIO-TIC was launched in 2012, as an FP7 project, with the aim to establish an overview of the barriers to biotechnology innovation and propose solutions to overcome them.

BIO-TIC has now published a series of videos that explain the rationale and objectives of the project and the three roadmaps that it is developing.

In the first video Antoine Peeters, Manager for Industrial Biotechnology at EuropaBio, gives an overview of the BIO-TIC project; its main activities and current status; the business cases, the project’s anticipated impact and future actions. This video is embedded at the end of this blog

Pádraig Naughton, Cefic innovation manager, features in a video explaining Cefic's role in the BIO-TIC project and outlining how wider use of industrial biotechnology (IB) can help the chemical industry grow.

A major milestone in the BIO-TIC project is the development of three roadmaps: market, technological, and non-technological. The project has recently released the second draft versions of the roadmaps which can be downloaded from the project website.

Anna Saarentaus, Principal at Pöyry, talks about the market drivers related to the various product segments and gives an overview of the projected use of IB in Europe by 2030. This video gives a comprehensive overview of the market potential for industrial biotechnology and of the value chain composition and stakeholders in various product segments and is an excellent introduction to the market roadmap.

The technological roadmap aims to gain insight into the R&D related hurdles that are impeding the full realisation of Europe’s IB market potential in 2030. In addition, the roadmap seeks to set priorities in terms of R&D and other actions to overcome the R&D barriers. In the video introducing the technological roadmap Elsbeth Roelofs, Senior Business Consultant at TNO, gives an overview of the R&D hurdles in Industrial Biotechnology in Europe and explains how the BIO-TIC roadmaps can help to overcome them.

The non-technological roadmap aims to identify regulatory and non-technological hurdles that may inhibit innovation and prevent the realisation of the market and technological potential of IB. Furthermore, the non-technological roadmap seeks to propose solutions to these hurdles by confronting theory and practice. The non-technological roadmap is introduced in a video with Antoine Peeters of EuropaBio who gives an overview of the non-technological hurdles of IB and explains how the BIO-TIC roadmaps will contribute to further develop the non-technological opportunities for IB applications in Europe.

More information
Input from the market and experts in industry and research are critical to build a basis for the roadmaps and to ensure that actions are developed which best fit the needs of this sector.  SusChem, Cefic and the BIO-TIC partners welcome any comments on the current draft documents. You can submit comments via email.

For more information on the BIO-TIC project and the business-case workshops visit the project website or contact Pierre Barthélemy, Innovation Manager at Cefic.

Friday, 25 July 2014

SusChem Stakeholder Interviews from #SusChem10

A new video of interviews from the 2014 SusChem Stakeholder event in mid June has just been published (see below). The video outlines SusChem’s rationale, vision, achievements and future goals.

Since it launch in 2004, SusChem has made many significant achievements - including the initiation of projects worth more than € 1.5 billion in FP7, its visionary flagship projects such as the Smart Energy Home, the F3 Factory and Integrated Biorefinery, and more recently the launch of two large Public-Private-Partnerships (PPPs) under Horizon 2020 : SPIRE and the BBI JTI.



The video features interviews with Clara de la Torre of the European Commission, Gernot Klotz of Cefic, Peter Nagler from Evonik and Louis Neltner of Solvay. The short video covers topics such as SusChem’s role in tackling societal challenges, the role of PPPs, and how Horizon 2020 will help accelerate innovation in Europe.

SusChem’s vision is for a competitive and innovative Europe where sustainable chemistry and biotechnology together provide solutions for future generations.

For more information on SusChem activities and the new SusChem SIRA contact Jacques Komornicki, SusChem Coordinator at Cefic. The SusChem website is at http://www.suschem.org.

EFIB2014 hosts BIO-TIC Building Block Workshop

The Seventh European Forum for Industrial Biotechnology (IB) and the Biobased Economy (EFIB2014) takes place in Reims, France from 30 September to 2 October and will be one of the events of the year on the exciting and rapidly developing European sustainable biobased economy scene. And SusChem FP7 project BIO-TIC will be contributing with a special workshop on biobased chemical building blocks.

The agenda for EFIB2014 is now confirmed with over 15 countries represented on the conference programme and plenary highlights including debate on the policy agenda for the European bioeconomy, sessions on future feedstocks including what the shale gas boom might mean for Europe's transition to a biobased economy, and opportunities to help define the value chain for a selection of biobased materials. A closing panel session will define opportunities for improving the sustainability profile of industrial production.

EFIB2014 takes place in association with IAR, EuropaBio and Smithers Rapra and will build on the success of EFIB2013.

Chemical Building Blocks
BIO-TIC’s workshop will debate what we need to do to build the foundations for the biobased chemicals industry in Europe. In 2013, the demand for biobased chemical building blocks in the EU was estimated at € 1 billion. By 2030 this is estimated to grow to between € 4.8 and 10.4 billion.

Despite the significant societal, environmental and economic advantages associated with using biobased chemical building blocks, many hurdles exist to their full implementation. These hurdles must be addressed to realise the full market potential for biobased chemical building blocks in the EU and include:

  • Securing a large enough supply of feedstock and at a price which is economically attractive compared to elsewhere in the world.
  • Uncertain definitions, for example for waste, hinder the exploitation of novel and cheap waste streams.
  • Lack of political support for chemical building blocks production, resulting in a lack of confidence from investors and users.
  • Uncertainty surrounding the potential impact of the increasing appetite for shale gas.

The BIO-TIC workshop takes place on the afternoon of 1 October at EFIB2014 and will verify that the hurdles already identified within the project are relevant and will develop concrete and actionable solutions to overcome them. The project focuses on the following chemical building blocks: 3HPA, succinic acid, PDO, furfural, and isoprene as the chemical building blocks that have the highest potential for deployment in the EU.

The workshop will seek to answer the key questions surrounding the production and use of chemical building blocks in Europe, including:

  • Should the EU focus on a broad chemical building block portfolio or should it reap the benefits from its strong R&D base and the current developments in favour of shale gas to develop a competitive advantage in biomass derived aromatics and C3/C4 chemicals?
  • Should the EU focus on improving existing technologies, fine and speciality chemicals where quality is crucial or focus on developing completely new technologies? 
  • Is it feasible or desirable to develop an internationally harmonised framework to allow international trade in biobased chemical building blocks?
  • How do we improve the cost-competitiveness of EU chemical building blocks production?
  • Should we introduce a specific mandate for bio-based chemicals in the EU or would tax incentives or infrastructure grants be more effective?
For more information on EFIB2014, including how to register, visit the conference website.


What is BIO-TIC?
BIO-TIC is a three year project, funded by the European Commission, which aims to identify the hurdles to IB and to develop solutions to overcome them, thereby unlocking the massive potential for this key technology in Europe. The project focuses on five product groups which have significant potential for Europe and which have the potential to introduce cross-cutting technology ideas. These product groups are:

  • Biobased chemical building blocks 
  • Bioplastics (PHA and PLA)
  • Biosurfactants
  • Advanced biofuels
  • CO2 based chemicals

Based on these business cases, the project is developing three in-depth “bio-roadmaps”. These will focus on the market potential, R&D priorities and non-technological hurdles of IB innovation. In particular, the market roadmap will provide market projections up to 2030. The technology roadmap will focus on setting R&D priorities and identifying needs for pilot and demonstration of plant activities. Last but not least, the non-technological barriers roadmap will identify regulatory and non-technological hurdles that may inhibit industrial biotech innovation reaching new market opportunities. The second draft versions of the roadmaps are already online while the final version will be released in July 2015.

All the BIO-TIC roadmaps, can be downloaded from the BIO-TIC Partnering Platform and for more information about the BIO-TIC FP7 project website.

Tuesday, 15 July 2014

Who is Europe’s Most Innovative CTO?

Who is the most innovative European technology leader you know? Spinverse Ltd. and EIRMA, the European Industrial Research Management Association, have launched this year's quest for Europe's Chief Technology Officer (CTO) of the Year. And they are looking for your nominations.

The CTO of the Year award is designed to highlight the role of the most prominent leaders of technology-based growth, promoting innovations to renew European industry and boosting Europe’s competitive advantage. The winner does not have to be CTO by title, however, he or she must be responsible for technology and its development in their company. The competition is based on an open call for nominations, across industry sectors and across Europe.
 
The award will be given to the most innovative technology leader, bringing significant value to their company’s growth through technology. An inspiring team-builder and a leader, he or she must be a passionate communicator of the benefit of technology to all stakeholders in an understandable way. The company represented by him or her will have an innovative and competitive - or an exciting, emerging - technology-enabled offering in Europe and globally.

As Robert-Jan Smits, Director-General for Research and Innovation, European Commission says: "Europe needs to celebrate those who advance technology and innovate. Initiatives like the ‘CTO of the Year award’ are very welcome as they lead to role models and further strengthen innovation in Europe."

More information
For more information, visit http://www.ctoeurope.net. Nominations are open until August 24th. You can also follow the award on Twitter at @CTO_Europe.

Friday, 11 July 2014

SusChem: The Story So Far

As part of our 10 year anniversary celebrations an extended video on the how, what and why of SusChem has been produced. Featuring a host of SusChem personalities that have been involved in SusChem over its first 10 years, the video covers the launch of the platform, its challenges, how we work together and its key achievements so far. The video then goes to look at the new Strategic Innovation and Research Agenda (SIRA), our PPPS (SPIRE and the BBI JTI), the platform's future aspirations and, most importantly, how you can get involved with our activities now. Enjoy! 


Happy Birthday SusChem!



You can download an executive summary of the draft SusChem SIRA here.

To find our more about SusChem and its activities visit our website or contact Jacques Kormonicki, the SusChem coordinator at Cefic. Join us today!


Thursday, 10 July 2014

Formulation: Recognising a Key Enabling Technology for SusChem

At the 10th Anniversary SusChem Stakeholder Meeting (#SusChem10), held last month (June 2014) in Brussels, participants contributed to the development of the SusChem Strategic Innovation and Research Agenda (SIRA). The SIRA will form the basis of SusChem’s input to forthcoming calls for the European Commission’s Horizon 2020 programme and other European and national research and innovation programmes. The SIRA highlights the importance of sustainable chemistry and biotechnology in responding to the key Societal Challenges facing Europe and addressed by Horizon 2020 as part of the EU’s Europe 2020 growth strategy

In this special article SusChem board member Prof Rodney Townsend (above) outlines the opportunities for SusChem in the Health and Wellbeing area and how the stakeholder event highlighted a new area for potential SusChem research and innovation activities.

On 11 and 12 June at the Stakeholder Event breakout sessions were held to address each Societal Challenge (SC) addressed in the SIRA. Conference participants commented on and added to draft SIRA documents for each SC which had been prepared in advance of the meeting.

Although health and well-being topics were part of the initial discussions when SusChem was first established in 2004, to date SusChem has not considered in depth how innovative sustainable chemistry could deliver health benefits, generally leaving this to Horizon 2020 activities linked more strongly to the pharmaceutical industries, such as the Innovative Medicines Initiative, the Active and Assisted Living Programme and the Joint Programming Initiative on Antimicrobial Resistance.

SusChem well-being
However, it is recognised that there are a number of areas where SusChem could complement these activities, which are critically important if the objectives of Horizon 2020’s SC1 (‘Health, demographic change and wellbeing’) are to be delivered.

A number of topics have already been highlighted in personalised diagnosis using imaging; and responsive materials for prosthetic devices including:
  • Innovative further development of highly sensitive imaging technologies for tumours, ischaemia and neurodegeneration using more specific and multifunctional chemical contrast agents and point-of-care diagnostics: an exciting prospect is to improve the specificity of expensive chemical markers, thus simultaneously increasing sustainability and reducing use of expensive reagents. 
  • Further development of technologies that assist and enable those who either are partially and progressively disabled to continue to contribute positively to society for longer: Here, we envisage an enhanced role for new (‘smart’) materials, such as haptic (reactive to touch or other sensory input), photoactive or piezoelectric polymers, as well as improved prosthetic devices and biomedical implants containing improved biocompatible soft materials for artificial limbs and the like.
Formulation
In addition at the Stakeholder Meeting a key issue came to the fore during breakout discussions: formulation. This is an area that is often taken for granted, yet is of profound importance across the whole of sustainable chemical technology, pharmacology and biotechnology. Formulation comprises a set of key skills and technologies that are absolutely critical for bringing many new inventions and advances in technologies to market in nearly every industry sector.

For example, starting with health, it is fine to design at a molecular level a new contrast agent that can so specifically target characteristic moieties present in a tumour that it can lead to unambiguous identification of the location, size and nature of a tumour. But, can one also design a suitable vehicle for that contrast agent that will ensure that the contrast agent is dispersed quickly through to all the organs in the body, is kept stable as it is dispersed, and delivered in a targeted manner?

Designing a suitable vehicle to achieve this is what formulation is all about. And successful formulation technology is not just important for health applications. It forms the basis of many businesses beyond medical and/or pharmaceutical, including the processing, manufacture and delivery-in-use of foods, personal products, cosmetics, and paints. It also has a role in crude oil extraction, including enhanced recovery concepts such as ‘fracking’, vehicle fuel or lubrication systems and very many other areas.  

The theory that underpins formulation is primarily physico-chemical and was traditionally referred to as ‘colloid science’.  It is concerned with the quantification of the forces that operate at interfaces between discrete physical domains, and how these forces operate and change over a hierarchy of length and time scales in different types of colloidal systems for example suspensions, sols, pastes, gels, foams, emulsions, micro-emulsions, gels, polymer and fat crystal networks, complex fluids and liquid crystals.

These forces combine to yield the observed useful properties of these systems including targeted delivery, visco-elasticity, opalescence, thixotropy, adherence and ‘spreadability’, softness, and dispersibility etc. They also are key to the delivery of product characteristics under different physical and chemical conditions such as the clarity and response rate of a LCD phone display, when an ice cream will soften and melt, how long it takes for an emollient hand cream to spread and penetrate skin, the touch or taste or smell of a food or medicine, how easy a medicine is to swallow and how fast the active components ingest through the stomach and intestinal walls amongst many other examples.

A new SusChem KET?
Although the physics underpinning these phenomena is fairly well understood, this understanding does not in itself lead one to be able to a priori formulate a product with the desired properties. The ability to do this lies with physical and synthetic chemists together with chemical and process engineers and comprises a highly valuable set of skills, based on a sound knowledge of theory and years of experience. But this skill base, so important for future innovation, is declining across Europe as a whole.

The Stakeholder Meeting highlighted the need to nurture and build this skill set as a SusChem key enabling technology (KET) that is applicable across and along value chains that cover many different industry sectors.

In his closing remarks at the 12th Stakeholder Meeting, SusChem Chairman Dr Klaus Sommer emphasised the need for us to highlight “formulation for delivery” in the SusChem SIRA. This will probably now result in the inclusion of a proposal for a Horizon 2020 Coordination and Support Action (CSA) in the SIRA that would bring the chemical, biotechnological and pharmaceutical sectors together to exchange information and enhance each other’s innovative skills in formulation.

For more information on SusChem activities and the new SusChem SIRA contact Jacques Komornicki, SusChem Coordinator at Cefic.

Wednesday, 9 July 2014

Bio Based Industries JTI: A Major Advance towards the Bioeconomy

Today (July 9) the European Technology Platform (ETP) for Sustainable Chemistry (SusChem) welcomes the launch of the Bio Based Industries Joint Technology Initiative (BBI JTI). This major Public-Private-Partnership (PPP) represents a significant step forward to the realisation of a European bioeconomy.

SusChem has actively supported the development of the BBI JTI and looks forward to working with the initiative to deliver a sustainable, competitive economy for Europe able to tackle some of our biggest societal challenges and bioeconomy opportunities.

The BBI JTI is being launched with six other JTIs (including JTI on ‘Fuel Cells and Hydrogen’ and ‘Innovative Medicines’) at an event with European Commission President Barroso, Vice Presidents Neelie Kroes and Siim Kallas, and Máire Geoghegan-Quinn, European Commissioner for Research, Innovation and Science (all pictured below at the BBI JTI stand). Together, the JTIs represent a significant joint public-private investment in research and innovation for Europe’s future.


Bio Based Innovation
The BBI JTI will enable a €3.7 billion injection into the European economy between 2014 and 2024, with €975 million provided by the European Commission and €2.7 billion from the Bio-based Industries Consortium (BIC), to develop the emerging bioeconomy. The JTI will finance research and innovation projects and create new and novel partnerships across industry sectors (including agriculture, technology providers, forestry/pulp and paper, chemicals and energy).

The aim of the BBI is to use Europe's untapped biomass and wastes as feedstock to make greener, sustainable everyday products and renewable feedstock.

“At the heart of this initiative are advanced biorefineries and innovative technologies that use sustainable chemistry to convert renewable resources into sustainable chemicals, materials and fuels,” says Dr Gernot Klotz, Executive Director Research at Cefic and SusChem board member.

“The BBI JTI can help develop the building blocks needed to shift from a fossil- and imports-based society to increase the EU’s rate of economic growth, boost jobs – especially in rural areas, rejuvenate industries and reduce greenhouse gas emissions,” he continues. “New bio-based industries can increase the competitiveness of the European economy through re-industrialisation and sustainable growth along with other Key Enabling Technologies.”

Four of the six main Key Enabling Technologies (KETs) identified to be critical to strengthening Europe’s industrial and innovation capacity are from the chemical sector: advanced materials, industrial biotechnology, nanotechnology and advanced manufacturing.

BBI launch


Opening the launch of the JTIs this afternoon José Manuel Barroso (above), President of the European Commission, said: "Only if the best brains from academia, industry, SMEs, research institutes and other organisations come together can we successfully tackle the huge challenges that we are facing. This is what public-private partnerships are about, the joining of forces to make the lives of Europeans better, create jobs and boost our competitiveness. We are committed to prioritising the impact of the European budget on the recovery, and these partnerships are doing just that, with first calls for proposals for € 1.1 billion to be matched by industry, within a package representing an overall € 22 billion boost to growth and jobs creation over seven years. They will continue delivering results that no single country, company or even the European Union as such would achieve alone."

The launch of first calls comes almost exactly one year after the European Commission put forward the Innovation Investment Package, a set of proposals to establish seven public-private and four public-public partnerships (including SPIRE, see below).

Commenting on the BBI launch today Máire Geoghegan-Quinn, European Commissioner for Research, Innovation and Science, said: "The bioeconomy has huge potential that is attracting investments all around the world. With this new partnership, we want to harness innovative technologies to convert Europe’s untapped renewable resources and waste into greener everyday products such as food, feed, chemicals, materials and fuels, all sourced and made in Europe."

Peder Holk Nielsen, CEO of Novozymes, added on behalf of the industry partner, the Bio-based Industries Consortium (BIC): “The BBI is an unprecedented public-private commitment because of its focus on bringing bio-based solutions to the market. It is an opportunity to deliver sustainable growth in European regions and to reverse the investment trend currently going to other regions of the world.”


Concluding the launch event Commissioner Máire Geoghegan-Quinn (above) said: "As we heard earlier today, only through joint investments in developing our research and innovation capacity can we create the new jobs and growth to overcome the current economic crisis. The challenge is, of course, to make sure that such investments deliver tangible impacts: to help accelerate the development of new technologies and innovations, to generate new markets for innovative products and services; and to deliver good jobs and major benefits to society. I am confident that the JTIs presented here will live up to this challenge. The first calls for proposals illustrate the kind of activities that JTIs will support in our goal of accelerating the deployment of great ideas from the lab into the market – for example large scale demonstrators, testing and prototyping."

BBI and SPIRE together
The BBI JTI builds on ‘SusChem inspired’ projects such as EUROBIOREF: one of three large FP7 projects in a joint call on advanced biorefineries that responded to SusChem’s visionary project: ‘The Integrated Biorefinery’. Innovations from other SusChem FP7 projects such as the F3 Factory will also contribute to the integration of bio based processes into the economy.

“The BBI JTI is one of two major PPPs that SusChem is proud to have inspired: the other being the Sustainable Process Industry through Resource and Energy Efficiency (SPIRE) PPP,” says Dr Klotz. “SPIRE and the BBI JTI will work closely together along defined areas of common interest and will use their synergies to help deliver high resource and energy efficiency that can lay the foundation of the circular economy in Europe, alongside the materials programme of SusChem.”

BBI explained 
The BBI JTI is a €3.7 billion Public-Private Partnership (PPP) between the EU and the Bio-based Industries Consortium (BIC). The BBI is dedicated to realising the European bioeconomy potential, turning biological residues and wastes into greener everyday products through innovative technologies and biorefineries, which are at the heart of the bioeconomy. The Bio-based Industries Consortium - the industrial partner in the PPP - is constituted by a unique mix of sectors including agriculture, agro-food, technology providers, forestry/pulp and paper, chemicals and energy. A short video  explaining what the BBI JTI is all ablout has also been published (see below).


A fact sheet on the BBI and its activities is available and more information can be found at the BBI website.

An Info Day on the BBI will take place on 2 September 2014 in Brussels and will be a 'must-attend' event for all stakeholders interested in understanding the BBI rules for participation.

Five value chains
Organised in five value chains – that range from primary production to consumer markets – the BBI will help fill the innovation gap between technology development and commercialisation, sustainably realising the potential of bio-based industries in Europe.

The BBI is a shift from a fossil- and imports-based society to increase Europe’s share of sustainable economic growth, and is expected to create tens of thousands of jobs (80% in rural areas), revitalise industries, diversify farmers’ incomes, and reduce GHG emissions by at least 50% in comparison to fossil-based applications.

The aim of the BBI is to use Europe's untapped biomass and wastes as feedstock to make fossil-free and greener everyday products. At the heart of it are advanced biorefineries and innovative technologies that will convert renewable resources into sustainable bio-based chemicals, materials and fuels.

The BBI will manage the investments in the form of research and innovation projects that are defined in annual Calls for Proposals and implemented across European regions. In line with Horizon 2020 rules, all stakeholders are invited to submit innovative proposals and demonstrate progress beyond state-of-the-art.

The BBI is dedicated to realising the European bioeconomy potential, turning biological residues and wastes into greener everyday products through innovative technologies and biorefineries, which are at the heart of the bioeconomy.

The BBI is about connecting key sectors, creating new value chains and producing a range of innovative bio-based products to ultimately form a new bio-based community and economy.

Bio-based Industries: using renewable natural resources and innovative technologies for greener everyday products developing new value chains for bio-based industries, from primary production to consumer markets;
  • Using innovative technologies to turn biological residues and wastes into greener everyday products;
  • Moving from fossil-based to biobased products: planting the seeds for the European circular economy;
  • Supporting regional development by diversifying the local economy;
  • Promoting the opening of new markets for bio-based products and applications “Made in Europe”.
The BBI JTI will help create new jobs, especially in rural regions, and offer Europeans new and sustainable products sourced and produced locally. New bio-based industries can increase the
competitiveness of the European economy through re-industrialisation and sustainable growth.

The development of new bio-based products and markets based on smart and efficient use of resources will diversify industries’ revenue streams.

The BBI is expected to bridge European research knowledge with commercial scale bio-based products, making full use of European scientific and technological knowledge. The BBI should benefit all Member States where regions can play an important role through their Smart Specialisation Strategies.

Seven JTIs
The BBI was one of seven JTIs launched at a special event in Brussels on 9 July. Fact sheets on all seven JTI are available via the links below:
For more information, please visit the SusChem website or contact Esther Agyeman-Budu, Cefic communication manager for research and innovation.

An extended SusChem 10th Anniversary video describing the platform, its achievements and its contribution to BBI has also been published on YouTube.